Giugliano, R. P., Pedersen, T. R., Saver, J. L., Sever, P. S., Keech, A. C., Bohula, E. A., . . . Sabatine, M. S. (2020). Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis. Stroke (1970), 51(5), 1546. https://doi.org/10.1161/STROKEAHA.119.027759
Citace podle Chicago (17th ed.)Giugliano, Robert P., et al. "Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis." Stroke (1970) 51, no. 5 (2020): 1546. https://doi.org/10.1161/STROKEAHA.119.027759.
Citace podle MLA (9th ed.)Giugliano, Robert P., et al. "Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis." Stroke (1970), vol. 51, no. 5, 2020, p. 1546, https://doi.org/10.1161/STROKEAHA.119.027759.